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Abstract
In the hypertrophied human heart, fatty acid metabolism is decreased and glucose utilisation is increased. We hypothesized
that the sarcolemmal and mitochondrial proteins involved in these key metabolic pathways would mirror these changes,
providing a mechanism to account for the modified metabolic flux measured in the human heart. Echocardiography was
performed to assess in vivo hypertrophy and aortic valve impairment in patients with aortic stenosis (n=18). Cardiac
biopsies were obtained during valve replacement surgery, and used for western blotting to measure metabolic protein
levels. Protein levels of the predominant fatty acid transporter, fatty acid translocase (FAT/CD36) correlated negatively with
levels of the glucose transporters, GLUT1 and GLUT4. The decrease in FAT/CD36 was accompanied by decreases in the fatty
acid binding proteins, FABPpm and H-FABP, the b-oxidation protein medium chain acyl-coenzyme A dehydrogenase, the
Krebs cycle protein a-ketoglutarate dehydrogenase and the oxidative phosphorylation protein ATP synthase. FAT/CD36 and
complex I of the electron transport chain were downregulated, whereas the glucose transporter GLUT4 was upregulated
with increasing left ventricular mass index, a measure of cardiac hypertrophy. In conclusion, coordinated downregulation of
sequential steps involved in fatty acid and oxidative metabolism occur in the human heart, accompanied by upregulation of
the glucose transporters. The profile of the substrate transporters and metabolic proteins mirror the metabolic shift from
fatty acid to glucose utilisation that occurs in vivo in the human heart.
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Introduction
Under normal physiological conditions, the healthy adult heart
derives 60–70% of its energy from the b-oxidation of long chain
fatty acids, with the remainder predominantly from carbohydrate
sources, such as glucose [1,2]. Fatty acids are a more energy dense
fuel, but require more oxygen for a given amount of ATP formed,
when compared with glucose (reviewed in [3]). Therefore,
increasing glucose metabolism at the expense of fatty acid
metabolism may be beneficial when oxygen is limited. In patients
with cardiac hypertrophy, fatty acid utilisation is decreased and
glucose utilisation is increased [4,5]. This metabolic shift is
proportional to the extent of cardiac hypertrophy, as fatty acid
uptake and oxidation inversely correlate with left ventricular mass
and end-diastolic diameter [4,6,7].
The underlying mechanisms by which fatty acid utilisation is
decreased in cardiac hypertrophy are not fully understood. Biopsies
taken from patients with heart failure have reduced mRNA
expression of the mitochondrial genes medium chain acyl-coenzyme
A dehydrogenase (MCAD), carnitine palmitoyl transferase I (CPT1)
and citrate synthase [8,9,10,11]. However, a greater understanding
of how metabolic proteins inthe various pathways change in relation
to each other will give a greater insight into the mechanisms
underpinning regulation of in vivo metabolic flux in the human heart.
Sarcolemmal fatty acid transporters are the primary regulated
step in cardiac fatty acid metabolism. A number of proteins are
involved in cardiac fatty acid uptake, including fatty acid
translocase (FAT/CD36), plasma membrane and heart-type
cytosolic fatty acid binding proteins (FABPpm and H-FABP)
[12,13,14]. These fatty acid transporters are located at different
positions in relation to the sarcolemma; FABPpm associated with
the sarcolemmal extracellular surface, FAT/CD36 within the
transmembrane region, and H-FABP within the cytosol
[13,14,15,16,17]. The hypothesised mechanism of action of these
fatty acid transporters is a co-operative channelling of the fatty
acid into the cell [18]. In the heart, FAT/CD36 is hypothesised to
be the key regulated step in fatty acid uptake, determining the
overall rate of entry into the cardiomyocyte [19,20]. The role of
FAT/CD36 in fatty acid uptake is analogous to that of the glucose
transporter GLUT4 in cardiac glucose uptake, both are the
primary steps in regulating the metabolism of their respective
substrates [21,22]. However, the relationship between these two
opposing substrate transporters and their relationship to disease
severity in the human heart has not been investigated.
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regulated in the failing rat heart, in proportion to fatty acid
metabolic rates and contractile function [23]. Here we measured
protein levels of the fatty acid and glucose transporters in the
hypertrophied human heart, and their relationship to key
downstream proteins involved in oxidative metabolism. We
hypothesised that FAT/CD36 protein levels would be inversely
related to glucose transporter levels, mirroring the metabolic
switch from fatty acid to glucose metabolism, and that this would
be associated with a downregulation of oxidative metabolic
proteins and proportional to disease severity in patients with
aortic stenosis.
Methods
Patient selection
Patients undergoing elective valve replacement for aortic
stenosis, with or without coronary artery revascularisation, were
recruited over a period of 6 months (n=18). The investigation
conforms to the principles outlined in the Declaration of Helsinki
and recruitment commenced after approval from the South
Birmingham Ethics Committee and with full informed written
consent from the patients. Patients with complicating diseases,
such as diabetes mellitus, were excluded, with the exception of
those with hypertension, angina pectoris and hyperlipidaemia. All
patients had pure aortic stenosis with no regurgitation.
Pre-operative 2D trans-thoracic echocardiography was per-
formed on all patients. M-mode measurements of septal and
posterior wall thickness and left ventricular diastolic diameter, at
the level of the chordae tendinae, were taken using a leading edge
to leading edge technique. These measurements were used to
calculate left ventricular mass using the American Society of
Echocardiography cube formula and indexed to body surface area,
to give left ventricular mass index (LVMI), an indicator of the
degree of hypertrophy. Left ventricular ejection fraction was
calculated using the Simpson’s biplanar method. Patients were
given their usual medications prior to surgery, which included
aspirin, statins, b-blockers, angiotensin-converting enzyme inhib-
itors and calcium channel blockers.
Sample collection and western blotting
Cardiac biopsy samples were taken from the ventricular apex
and atria (n=18), and samples were immediately frozen in liquid
nitrogen. Cell lysates were prepared from the tissue and, for each
sample, equal concentrations of total protein were separated on
12.5% SDS-polyacrylamide gels [23]. Gels were incubated in
transfer buffer with Immobilon-P membranes (Millipore, UK) and
extra thick chromatography paper (BioRad, UK) for 30 min, and
transferred using semi-dry transfer apparatus (Biorad, UK) at 0.07
A per gel for 1 h. Membranes were incubated with primary
antibodies overnight, diluted in Tris-buffered saline containing 5%
(wt/vol) milk powder. FAT/CD36 was detected with the
monoclonal antibody MO25, a gift from Dr Narendra Tandon
(Otsuka Maryland Medicinal Laboratories, MD) and FABPpm
was detected using a primary antibody donated by Dr Jorge
Calles-Escandon (Wake Forest University School of Medicine,
NC). Primary antibodies raised against H-FABP (also called
cFABP) and GLUT1 were purchased from Abcam (Cambridge,
UK). Antibodies raised to medium chain acyl-coenzyme A
dehydrogenase (MCAD) and a-ketoglutarate dehydrogenase were
purchased from Santa Cruz (USA). Prof. Geoff Holman
(University of Bath, UK) kindly donated the primary antibody to
GLUT4. Antibodies raised to complex I and ATP synthase of the
electron transport chain (ETC) were purchased from MitoSciences
(USA). Appropriate horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz, USA) were diluted 1:3500 in Tris-buffered
saline containing 5% (wt/vol) milk and incubated with the
membranes for 2 hours. Bands were quantified using UN-
SCAN-IT gel software (Silk Scientific, USA), and all samples
were run in duplicate on separate gels to confirm results. Even
protein loading between samples and successful transfer were
confirmed using Ponceau staining (Sigma, UK). Protein levels
were related to internal standards, run on all gels, to ensure
homogeneity between samples and gels.
Fasting plasma metabolites
Blood was collected prior to induction of anaesthesia or
administration of heparin, plasma was separated by centrifugation
and stored at 280uC. Concentrations of plasma glucose, free fatty
acids, triacylglycerol and cholesterol were measured using an
automated spectrophotometric analyser (Monarch Laboratories,
USA).
Statistics
Correlations between data sets were calculated using the
Pearson correlation coefficient (PASW statistics version 18,
USA). All physical, clinical and molecular parameters were
correlated with each other, and the significant correlations
described in the results. Statistical significance was taken at
p,0.05.
Results
Clinical characteristics and plasma metabolites
In total, 18 patients were studied, 12 male and 6 female, aged
between 48 and 77 years and with a body mass index ranging from
20 to 34 (Table 1). According to the New York Heart Association
(NYHA) classification, 10 patients were class I, 5 were class II, 2
were class III and 1 was class IV, and two patients had prior
myocardial infarction (one class I and one class IV). Left
ventricular mass index, a measurement of the extent of cardiac
hypertrophy and disease severity, ranged from 80 to 190 g/m
2 in
the patient group. Left ventricular ejection fraction ranged from
28 to 58%, and there was a strong negative correlation between
LVMI and cardiac ejection fraction (r=20.69, p,0.001). Fasting
plasma metabolites are presented in Table 1.
Table 1. Patient Characteristics.
Physical Characteristics
Male gender 12/18
Age (years) 6962
Body weight (kg) 7864
Body mass index 2761
NYHA classification I, II, III and IV 55%, 28%, 11% and 6%
Left ventricular mass index (LVMI) (g/m
2)1 2 6 68
Ejection fraction (%) 5062
Fasting plasma metabolites (mmol/l)
Free fatty acids 0.7360.09
Triacylglycerol 1.6460.23
Cholesterol 3.5360.37
Glucose 6.3260.26
doi:10.1371/journal.pone.0026326.t001
Metabolic Proteins in the Human Heart
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mitochondrial metabolic proteins in the human heart
Relationships were identified between the different fatty acid
transporters present in the cardiac biopsies. Positive correlations
were found between FAT/CD36 and both H-FABP and FABPpm
protein levels (Figure 1) in the atria, demonstrating that changes in
the family of fatty acid transporters were co-ordinated.
FAT/CD36, the predominant fatty acid transporter in the
heart, showed positive relationships with other key downstream
proteins involved in mitochondrial oxidative metabolism. Positive
correlations were identified between FAT/CD36 and protein
levels of MCAD, a-ketoglutarate dehydrogenase and ATP
synthase (Figure 2) in the ventricular biopsies. MCAD is a
PPARa-regulated protein involved in b-oxidation, a-ketoglutarate
dehydrogenase is involved in the Krebs cycle and ATP synthase
phosphorylates ADP to ATP. The other fatty acid transporters did
not show a significant relationship with the mitochondrial
metabolic proteins.
Relationship between FAT/CD36 and glucose
transporters in the human heart
The heart can switch its substrate preference between fatty acid
and glucose metabolism, to provide ATP to power contraction
[24]. Negative relationships were identified between FAT/CD36
and the two glucose transporter isoforms expressed in the ventricle
(Figure 3). FAT/CD36 correlated negatively with both GLUT1
and GLUT4, thus, in those hearts with the lowest FAT/CD36
protein expression, there was a concomitant upregulation of both
glucose transporters. Negative correlations were also found
between GLUT4 and both MCAD protein levels (r=20.62,
p,0.01) and FABPpm protein levels (r=20.57, p,0.05). This
data is indicative of the switch between fatty acid and glucose
metabolism in the human heart.
Relationship between metabolic protein and disease
severity in the human heart
In heart disease, the decrease in fatty acid utilisation is
proportional to the extent of cardiac hypertrophy [4,7]. FAT/
CD36 correlated negatively with LVMI, thus, patients with the
greatest cardiac hypertrophy had the lowest FAT/CD36 protein
levels (Figure 4). Similarly, protein levels of electron transport
chain complex I correlated negatively with LVMI. This was in
contrast to GLUT4, which demonstrated a positive correlation
with the extent of hypertrophy. We found no significant
correlations between plasma metabolites, extent of coronary
Figure 1. Positive correlations between fatty acid transporters
FAT/CD36, H-FABP and FABPpm in the human heart. Protein
levels are expressed in arbitrary units, relative to the internal standards.
doi:10.1371/journal.pone.0026326.g001
Figure 2. Positive correlations between FAT/CD36 and mito-
chondrial metabolic proteins including the b-oxidation protein
MCAD, the Krebs cycle protein a-ketoglutarate dehydrogenase
and ATP synthase in the human heart.
doi:10.1371/journal.pone.0026326.g002
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cardiac hypertrophy there was a shift from FAT/CD36 and
electron transport chain complex I protein expression, towards
GLUT4 protein expression in the ventricle of patients with aortic
stenosis.
Discussion
In this study on the human heart, we have shown that the
predominant sarcolemmal fatty acid transporter, FAT/CD36,
changed in unison with b-oxidation, Krebs cycle and oxidative
phosphorylation proteins, but inversely to the sarcolemmal glucose
transporters. The changes in substrate uptake proteins were
proportional to disease severity, as an increase in cardiac
hypertrophy was accompanied by decreased FAT/CD36 and
increased GLUT4. This shift from FAT/CD36 to GLUT4
mirrors the metabolic shift from fatty acid to glucose metabolism
that occurs with increasing hypertrophy [4,7].
The fatty acid transporters have received increasing interest in
recent years because of their involvement in the metabolic
dysfunction occurring in heart disease, diabetes and lipotoxicity
[23,25,26]. The positive relationship between FAT/CD36,
FABPpm and H-FABP in the present study demonstrates that
changes in these three transporters were co-ordinated. Their
cellular location indicates they may be involved in sequential steps
in the fatty acid uptake pathway, with FABPpm on the
extracellular leaflet binding the fatty acid, FAT/CD36 spanning
the membrane internalising the fatty acid, and H-FABP within the
cytosol transporting the fatty acid away [12,13,14]. Thus, a co-
ordinated decrease in all three transporters would help regulate
the overall process of fatty acid uptake. FAT/CD36 deficiency has
been identified in some patients with hereditary hypertrophic
cardiomyopathy, associated with a decreased myocardial uptake of
fatty acids [27], suggesting that fatty acid transport and
metabolism may be intricately linked to cardiac pathology.
In vivo measurements of fatty acid metabolism in patients with
cardiac hypertrophy have shown decreases in both myocardial
fatty acid uptake and oxidation [4,7]. Studies have reported
decreased expression of genes encoding mitochondrial fatty acid
oxidation genes, including MCAD and CPT1 [8,9,28]. The
relative decreases in FAT/CD36, MCAD, a-ketogluturate dehy-
drogenase and ATP synthase proteins in the present study
demonstrates that co-ordinated changes are occurring in sequen-
tial pathways involved in fatty acid metabolism, including fatty
acid uptake, b-oxidation, the Krebs cycle and oxidative phos-
Figure 3. Negative correlation between FAT/CD36 and the
glucose transporters GLUT1 and GLUT4 in the human heart.
doi:10.1371/journal.pone.0026326.g003
Figure 4. Relationship between metabolic proteins and disease
severity in the human heart. Negative correlations between left
ventricular mass index (LVMI) and protein levels of FAT/CD36 and
complex I of the electron transport chain. Positive correlation between
LVMI and GLUT4 protein levels.
doi:10.1371/journal.pone.0026326.g004
Metabolic Proteins in the Human Heart
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oxidation occurred independent of a decrease in fatty acid uptake,
cytosolic lipid accumulation and lipotoxicity may occur. Thus,
synchronised regulation of sequential pathways would ensure
deleterious intermediates did not accumulate within the cell. The
changes in a-ketoglutarate dehydrogenase and ATP synthase
indicate that oxidation of all mitochondrial substrates may be
downregulated, not just fatty acids. This is in agreement with the
decreased glutamate state 3 respiration rates measured in biopsies
from failing human hearts [29,30]. That the other fatty acid
transporters did not display a significant relationship with
downstream mitochondrial metabolic proteins was unexpected.
However, this could be due to the hypothesised predominant role
of FAT/CD36 in regulating the overall fatty acid uptake pathway
[19,20] or due to insufficient statistical power.
The heart has the metabolic flexibility to switch between
substrates, both acutely and chronically, according to the
physiological or pathological conditions. We have identified a
negative correlation between FAT/CD36 and the two glucose
transporters, indicating that under conditions when FAT/CD36 is
downregulated the capacity for glucose uptake by GLUT1 and
GLUT4 is increased. This balance between FAT/CD36 and
GLUT4 has been noted in animal models, as in diabetes or
following a lipid infusion the expression of FAT/CD36 increases
and GLUT4 decreases [31,32]. In patients with dilated cardio-
myopathy, fatty acid uptake is decreased and glucose uptake is
increased, indicating that sarcolemmal substrate uptake may be
changed in these hearts [4]. Regulating the expression of the
sarcolemmal substrate transporters would chronically alter the rate
of substrate uptake into the cell and have knock-on effects on
downstream substrate metabolism.
In patients with dilated cardiomyopathy, fatty acid uptake rates
correlate negatively with left ventricular end-diastolic diameter [4].
The decreasing protein levels of FAT/CD36 with increasing
cardiac hypertrophy in the present study provides a mechanism to
explain the findings in the former study. Our work on the
chronically infarcted rat heart supports these findings, as decreased
fatty acid transporter levels were found in the hypertrophied rat
heart and were related to decreased fatty acid utilisation and
decreased in vivo cardiac function [23]. In addition to changes in
fatty acid uptake, changes in fatty acid oxidation have also been
reported in human heart disease, and correlate with left
ventricular mass [7]. Studies on the mitochondrial electron
transport chain in the failing human heart by Scheubel et al
identified selective downregulation of complex I activity, while the
other complexes remained unchanged [33]. Similarly, the present
study showed that complex I protein levels were selectively
decreased in relation to increased cardiac hypertrophy. Taken
together, the decreased FAT/CD36 and increased GLUT4 with
cardiac hypertrophy resembles the decreased fatty acid metabo-
lism and increased glucose metabolism measured in vivo [4,5]. The
substrate transporters may serve to regulate flux into their
respective pathways, and aid switching the heart towards a more
oxygen efficient fuel under conditions in which oxygen availability
may be restricted. If this is the case, these transporters could be
attractive therapeutic targets.
A limitation of the present study is that we were unable to
include a control group due to lack of availability of biopsy tissue
from healthy individuals. However, our data clearly show a
relationship between disease progression and metabolic protein
levels. In addition, we were unable to distinguish between
sarcolemmal and microsomal FAT/CD36, due to small biopsy
sizes. However, the total pool of FAT/CD36 has previously been
shown to correlate positively with cardiac function and metabolism
in the failing rat heart [23].
In conclusion, in patients with aortic stenosis, FAT/CD36 was
downregulated whereas GLUT4 was upregulated with increasing
cardiac hypertrophy. Decreases in FAT/CD36 were accompanied
by decreases in other fatty acid transporters, b-oxidation, Krebs
cycle and oxidative phosphorylation proteins, and, in contrast, by
increases in both GLUT1 and 4 protein levels. The profile of
substrate transporters in the hypertrophied human heart was in
agreement with the changes in substrate metabolism measured in
vivo, suggesting that the sarcolemmal substrate transporters may be
involved in the metabolic shift from fatty acid to glucose utilisation
in cardiac hypertrophy.
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